Population Pharmacokinetic/Pharmacodynamic Models for P2Y12 Inhibitors: A Systematic Review and Clinical Appraisal Using Exposure Simulation

Chen, Jingcheng; Qu, Yuchen; Jiang, Muhan; Li, Haiyan; Cui, Cheng; Liu, Dongyang

doi:10.1007/s40262-023-01335-2

Cited by 3 publications

(1 citation statement)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings support the role of the interplay between the platelet ADP receptors in the pathogenesis of platelet thrombi, as suggested by the finding that their concomitant inhibition completely abolished shear-induced platelet aggregation [49]. Since the reduction in platelet aggregation is crucial to preventing cardiovascular events, including myocardial infarction, a number of compounds or active metabolites that antagonize ADP-induced platelet aggregation by blocking the P2Y12 receptor have been conceived [50].…”

Section: Role Of P2y12 and P2y1 In Adp-induced Platelet Activationsupporting

confidence: 65%

Current Strategies to Guide the Antiplatelet Therapy in Acute Coronary Syndromes

Russo,

Brookles,

Barale

et al. 2024

IJMS

View full text Add to dashboard Cite

The role of antiplatelet therapy in patients with acute coronary syndromes is a moving target with considerable novelty in the last few years. The pathophysiological basis of the treatment depends on platelet biology and physiology, and the interplay between these aspects and clinical practice must guide the physician in determining the best therapeutic options for patients with acute coronary syndromes. In the present narrative review, we discuss the latest novelties in the antiplatelet therapy of patients with acute coronary syndromes. We start with a description of platelet biology and the role of the main platelet signal pathways involved in platelet aggregation during an acute coronary syndrome. Then, we present the latest evidence on the evaluation of platelet function, focusing on the strengths and weaknesses of each platelet’s function test. We continue our review by describing the role of aspirin and P2Y12 inhibitors in the treatment of acute coronary syndromes, critically appraising the available evidence from clinical trials, and providing current international guidelines and recommendations. Finally, we describe alternative therapeutic regimens to standard dual antiplatelet therapy, in particular for patients at high bleeding risk. The aim of our review is to give a comprehensive representation of current data on antiplatelet therapy in patients with acute coronary syndromes that could be useful both for clinicians and basic science researchers to be up-to-date on this complex topic.

show abstract

Section: Role Of P2y12 and P2y1 In Adp-induced Platelet Activationsupporting

confidence: 65%

Current Strategies to Guide the Antiplatelet Therapy in Acute Coronary Syndromes

Russo,

Brookles,

Barale

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

Update on antithrombotic therapy and body mass: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and the European Society of Cardiology Working Group on Thrombosis

Gigante,

Tamargo,

Agewall

et al. 2024

European Heart Journal - Cardiovascular Pharmacotherapy

View full text Add to dashboard Cite

Obesity and underweight are a growing health problem worldwide and a challenge for clinicians concerning antithrombotic therapy, due to the associated risks of thrombosis and/or bleeding. This clinical consensus statement updates a previous one published in 2018, by reviewing the most recent evidence on antithrombotic drugs based on body size categories according to the World Health Organization classification. The document focuses mostly on individuals at the extremes of body weight, i.e. underweight and moderate-to-morbid obesity, who require antithrombotic drugs, according to current guidelines, for the treatment or prevention of cardiovascular diseases or venous thromboembolism. Managing antithrombotic therapy or thromboprophylaxis in these individuals is challenging, due to profound changes in body composition, metabolism and organ function, and altered drug pharmacokinetics and pharmacodynamics, as well as weak or no evidence from clinical trials. The document also includes artificial intelligence simulations derived from in silico pharmacokinetic/pharmacodynamic models, which can mimic the pharmacokinetic changes and help identify optimal regimens of antithrombotic drugs for severely underweight or severely obese individuals. Further, bariatric surgery in morbidly obese subjects is frequently performed worldwide. Bariatric surgery causes specific and additional changes in metabolism and gastrointestinal anatomy, depending on the type of the procedure, which can also impact the pharmacokinetics of antithrombotic drugs and their management. Based on existing literature, the document provides consensus statements on optimizing antithrombotic drug management for underweight and all classes of obese patients, while highlighting the current gaps in knowledge in these complex clinical settings, which require personalized medicine and precision pharmacology.

show abstract

Determination of Tricin in Rat Plasma by Uplc-Ms/Ms and its Pharmacokinetics

Wen,

Ma,

Zheng

et al. 2024

Preprint

View full text Add to dashboard Cite

Population Pharmacokinetic/Pharmacodynamic Models for P2Y12 Inhibitors: A Systematic Review and Clinical Appraisal Using Exposure Simulation

Cited by 3 publications

References 42 publications

Current Strategies to Guide the Antiplatelet Therapy in Acute Coronary Syndromes

Current Strategies to Guide the Antiplatelet Therapy in Acute Coronary Syndromes

Update on antithrombotic therapy and body mass: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and the European Society of Cardiology Working Group on Thrombosis

Determination of Tricin in Rat Plasma by Uplc-Ms/Ms and its Pharmacokinetics

Contact Info

Product

Resources

About